Literature DB >> 17260149

[Pharmaceutical therapy of diabetes mellitus type 2].

K Laubner1, J Seufert.   

Abstract

The sequelae and complications associated with type 2 diabetes mellitus can be reduced or inhibited by optimal therapy. Currently, a variety of medications are available for differentiated therapy, which should be used according to the German Diabetes Association Guidelines. Changes in lifestyle represent the basic therapeutic principle, and it is mandatory to continuously maintain these measures throughout life. If this is not adequately effective (HBA(1c) <6.5%), treatment with oral antidiabetic drugs (OAD) is necessary. Over time OAD monotherapy frequently fails, so that a combination of several oral antidiabetics is needed. The choice of oral antidiabetics is particularly dependent on the patient's body mass index and associated diseases. If combination therapy with OAD is not successful in achieving HbA1c values <6.5%, insulin therapy is required either in combination with OADs as a bedtime regimen or as intensive insulin therapy using both basal and short-term acting insulins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17260149     DOI: 10.1007/s00108-006-1789-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  21 in total

1.  Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

Authors:  Alex Wright; A C Felix Burden; Richard B Paisey; Carole A Cull; Rury R Holman
Journal:  Diabetes Care       Date:  2002-02       Impact factor: 19.112

2.  Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study.

Authors:  J Olsson; G Lindberg; M Gottsäter; K Lindwall; A Sjöstrand; A Tisell; A Melander
Journal:  Diabetologia       Date:  2000-05       Impact factor: 10.122

3.  Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

Authors:  A J Garber; T G Duncan; A M Goodman; D J Mills; J L Rohlf
Journal:  Am J Med       Date:  1997-12       Impact factor: 4.965

Review 4.  The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity.

Authors:  J E Gerich
Journal:  Endocr Rev       Date:  1998-08       Impact factor: 19.871

5.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

6.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

7.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

8.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

9.  The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

Authors:  J L Chiasson; R G Josse; J A Hunt; C Palmason; N W Rodger; S A Ross; E A Ryan; M H Tan; T M Wolever
Journal:  Ann Intern Med       Date:  1994-12-15       Impact factor: 25.391

10.  Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.

Authors:  Julio Rosenstock; David R Hassman; Robert D Madder; Shari A Brazinsky; James Farrell; Naum Khutoryansky; Paula M Hale
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.